{
  "abstract": "In the PETITE-DTG phase 1/2 open-label trial in South Africa, 41 term neonates born to virally suppressed mothers on dolutegravir (DTG)-based ART (Antiretroviral therapy) were randomised to 5 mg DTG as half a dispersible tablet (n=21) or oral dispersible film (n=20) every 48 hours for 2 weeks and then daily to day 28. The first DTG dose was administered at a median of 47 hours after birth, accounting for transplacental DTG exposure and alongside zidovudine postnatal prophylaxis. DTG plasma concentrations at 6–10 days showed similar geometric mean area under the curve (193.2 µg⋅h/mL) and met prespecified paediatric pharmacokinetic targets (geometric-mean C trough 2.1 µg/mL and Cmax 6.4 µg/mL). No adverse events were attributed to DTG; all 39 neonates completing follow-up remained HIV-negative. These data support guideline inclusion of 5 mg DTG from birth in term neonates, aligning with current ART regimens for older children.",
  "authors": [
    {
      "affiliations": [
        "Infectious Diseases, Sheikh Shakhbout Medical City, Abu Dhabi, Abu Dhabi, UAE",
        "United Arab Emirates University College of Medicine and Health Sciences, Al Ain, Abu Dhabi, UAE"
      ],
      "name": "Rachel Herbert"
    },
    {
      "affiliations": [
        "Institute for Global Health, University College London, London, UK"
      ],
      "name": "Marina Daskalopoulou"
    },
    {
      "affiliations": [
        "Lawson Unit, University Hospitals Sussex NHS Foundation Trust, Brighton, East Sussex, UK"
      ],
      "name": "Sonia Raffe"
    },
    {
      "affiliations": [
        "Vita-Salute San Raffaele University, Milano, Italy"
      ],
      "name": "Angelo Roberto Raccagni"
    }
  ],
  "title": "Research news in clinical context",
  "uid": "8c7dc879-6bc2-5d11-b210-431ba00205a7"
}